AstraZeneca Pharma India Limited (NSE:ASTRAZEN)
6,951.50
-155.00 (-2.18%)
Aug 31, 2026, 3:30 PM IST
AstraZeneca Pharma India Revenue
AstraZeneca Pharma India had revenue of 6.83B INR in the quarter ending June 30, 2026, with 29.73% growth. This brings the company's revenue in the last twelve months to 24.32B, up 31.10% year-over-year. In the fiscal year ending March 31, 2026, AstraZeneca Pharma India had annual revenue of 22.76B with 32.59% growth.
Revenue (ttm)
24.32B
Revenue Growth
+31.10%
P/S Ratio
7.17
Revenue / Employee
32.00M
Employees
600
Market Cap
174.27B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 22.76B | 5.59B | 32.59% |
| Mar 31, 2025 | 17.16B | 4.21B | 32.48% |
| Mar 31, 2024 | 12.96B | 2.93B | 29.17% |
| Mar 31, 2023 | 10.03B | 1.97B | 24.50% |
| Mar 31, 2022 | 8.06B | -79.60M | -0.98% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Emcure Pharmaceuticals | 96.83B |
| Piramal Pharma | 92.05B |
| Alembic Pharmaceuticals | 77.84B |
| Strides Pharma Science | 50.04B |
| Akums Drugs and Pharmaceuticals | 45.04B |
| Wockhardt | 36.53B |
| NATCO Pharma | 34.85B |
| Eris Lifesciences | 32.12B |
AstraZeneca Pharma India News
- 21 days ago - AstraZeneca Pharma India Quarterly report: Q1 2027 - Filings
- 2 months ago - AstraZeneca Pharma India appoints Mihir Parikh and Amay Ashok Pandey to key director roles - Business Upturn
- 2 months ago - AstraZeneca Pharma India appoints Praveen K Mittal as Director - Corporate Affairs - Business Upturn
- 2 months ago - AstraZeneca Pharma India announces resignation of senior management personnel - Business Upturn
- 2 months ago - AstraZeneca gets CDSCO approval to sell Enhertu in India for first-line HER2-positive breast cancer treatment - Business Upturn
- 3 months ago - Why are AstraZeneca Pharma shares down over 4% today? Explained - Business Upturn
- 3 months ago - AstraZeneca Pharma India Quarterly report: Q4 2026 - Filings
- 3 months ago - AstraZeneca Pharma India Annual report: Q4 2026 - Filings